Flatulence

Low-Dose Naltrexone in Gastroenterology: A Bonafide ‘Wonder Drug’

Retrieved on: 
Friday, May 3, 2024
Defecation, Irritable bowel syndrome, Ulcerative colitis, Inflammation, Gastroenterology, Crohn's disease, RLS, Restless legs syndrome, Research, IBD, Inflammatory bowel disease, Flatulence, Psoriasis, Health, Immune system, LDN, IBS, Medical device

Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.

Key Points: 
  • Dr. Weinstock's insightful piece sheds light on the potential of LDN as a novel therapeutic approach in the field of gastroenterology.
  • Low-dose naltrexone, traditionally known for its role in managing opioid and alcohol dependence, has emerged as a compelling option for addressing various gastrointestinal conditions.
  • Furthermore, Dr. Weinstock highlights the need for further research and clinical trials to fully elucidate LDN's therapeutic potential in gastroenterology.
  • For more information on Dr. Leonard Weinstock's insights into low-dose naltrexone in gastroenterology, please read his full article here .

Herbal medicinal product: Curcumae longae rhizomaArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Date, Ethanol, Patient, Physiology, Committee, Flatulence, Stomach, Digestion, Monograph, Mouth, Herbal medicine, Medicine, Medicinal plants

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of turmeric.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing turmeric.
  • Herbal medicines containing these turmeric preparations are usually available as herbal tea to be drunk and in solid or liquid forms to be taken by mouth.
  • Turmeric preparations may also be found in combination with other herbal substances in some herbal medicines.

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Asteraceae, Ethanol, Artichoke, Diarrhea, Cardoon, Spasm, Patient, Physiology, Monograph, Committee, Flatulence, Herbal medicine, Heartburn, Date, Allergy, Plant, Nausea, Sensation, Mouth, Water, Bloating, Liver, Bile, Medicine, Dietary supplement

Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Cynarae foliumArray,Array, C: ongoing call for scientific data

Herbal medicinal product: Melissae foliumArray, C: ongoing call for scientific data

Retrieved on: 
Wednesday, April 3, 2024
Patient, Monograph, Committee, Flatulence, Insomnia, Sleep, Anxiety, Herbal medicine, DSM-IV codes, Date, Wind, Mouth, Key, Bloating, Medicine, Dietary supplement

Overview

Key Points: 
  • Overview
    This is a summary of the scientific conclusions reached by the Committee on Herbal Medicinal Products (HMPC) on the medicinal uses of melissa leaf.
  • The HMPC conclusions are taken into account by EU Member States when evaluating applications for the licensing of herbal medicines containing melissa leaf.
  • Herbal medicines containing melissa leaf are usually available as a herbal tea to be drunk, and in solid and liquid forms to be taken by mouth.
  • Melissa leaf can also be found in combination with other herbal substances in some herbal medicines.

FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight

Retrieved on: 
Friday, March 8, 2024
Gastroesophageal reflux disease, Research, Heartburn, Blood, Diet, Cholesterol, Dietary supplement, Obesity, Dizziness, Pancreatitis, Vomiting, Health care, History, Thyroid cancer, Fatigue, Hypoglycemia, Acute kidney injury, Depression, Patient, Kidney disease, Abdominal distension, Burping, Cosmetics, Cardiovascular disease, Suicide, Weight, Stroke, Nausea, Diabetic retinopathy, Pancreas, Insulin, Blood pressure, Multimedia, Overweight, Diarrhea, Novo Nordisk, Vaccine, Safety, Heated tobacco product, Indigestion, Heart, Human services, Priority review, Division, Headache, Inflammation, FDA, Food, Weight loss, Thought, Heart rate, Gallstone, Risk, Animal, Allergy, Constipation, Death, Flatulence, Public

"This patient population has a higher risk of cardiovascular death, heart attack and stroke.

Key Points: 
  • "This patient population has a higher risk of cardiovascular death, heart attack and stroke.
  • Providing a treatment option that is proven to lower this cardiovascular risk is a major advance for public health."
  • Obesity or overweight affect approximately 70% of American adults.
  • Obesity and overweight are serious health issues that increase the risk for premature death and a variety of health problems, including heart attack and stroke.

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Psyllium, Key, Inhalation, Committee, Monograph, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Safety, Stomach, Rectum, Plantago, Rhinitis, Patient, Medicine, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae semenArray, C: ongoing call for scientific data

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Retrieved on: 
Friday, February 16, 2024
Key, Inhalation, Committee, Monograph, Diet, Conjunctivitis, Inflammation, Pain, Bronchospasm, Anaphylaxis, Hemorrhoid, Human, Eye, Allergy, Date, Defecation, Risk, Seed, Mouth, Constipation, Hypercholesterolemia, Safety, Irritable bowel syndrome, Stomach, Rectum, Rhinitis, Abdominal pain, Patient, Medicine, Disease, Bleeding, Abdominal distension, Anal, Herbal medicine, Flatulence, Failure, Water

Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Key Points: 


Herbal medicinal product: Plantaginis ovatae seminis tegumentumArray, C: ongoing call for scientific data

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Patient, Medical Subject Headings, Diarrhea, Flatulence, Marketing, European Commission, Agency, INN, Constipation, Risk, Extrapyramidal system, Opioid, ATC, Bowel obstruction, International, Syringe, European, Spinal cord, Injection, Nausea, Language, Brain, Abdominal pain, Laxative, Naltrexone, Morphine, Disorder, Chronic pain, Select, Anatomy, Medicine, Palliative care, Dialysis, IIA, Skin, Medical device

Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Relistor, methylnaltrexone bromide, Date of authorisation: 01/07/2008, Revision: 19, Status: Authorised

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
People, Medical Subject Headings, Peripheral, Diarrhea, Flatulence, Marketing, European Commission, Agency, INN, Constipation, Risk, Movement, Opioid, ATC, Pain, International, European, OIC, Spinal cord, Headache, Nausea, Language, Brain, Abdominal pain, Laxative, Cancer, Disorder, Tablet, Chronic pain, Select, Patient, Safety, Naloxone, Anatomy, Medicine, Bowel obstruction, Risk management, IIA, CHMP, Medical device

Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Moventig, naloxegol, Date of authorisation: 07/12/2014, Revision: 16, Status: Authorised

Human medicines European public assessment report (EPAR): Feraccru, ferric maltol, Date of authorisation: 18/02/2016, Revision: 18, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Flatulence, Diarrhea, Marketing, INN, Constipation, Woman, Iron, ATC, Capsule, International, Man, Language, Mouth, Abdominal pain, Chronic pain, European Medicines Agency, Select, Cell, Patient, Anatomy, IIA, Medical device

Human medicines European public assessment report (EPAR): Feraccru, ferric maltol, Date of authorisation: 18/02/2016, Revision: 18, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Feraccru, ferric maltol, Date of authorisation: 18/02/2016, Revision: 18, Status: Authorised